61P - Tumor-infiltrating lymphocytes/macrophages and clinical outcome in breast cancer

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Pathology/Molecular Biology
Translational Research
Presenter Yong-Seok Kim
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors Y. Kim, J. Kim
  • Surgery, Uijeongbu St. Mary's Hospital, 11765 - Uijeongbu City/KR

Abstract

Background

Breast cancer is composed of the malignant tumor cells and tumor microenvironment, which includes inflammatory cells. The inflammatory cells, known as lymphocytes and macrophages, regulate and release inflammatory mediators with pro-angiogenic or pro-metastatic effects in breast cancer. Tumor infiltrating lymphocytes(TILs) and tumor-associated macrophages(TAMs) are regarded to play a key role in progression and metastasis of various tumors. We evaluated their correlation with clinicopathologic parameters and prognosis in breast cancer.

Methods

A total of 73 patients with stage I to III breast cancer who underwent surgery at Uijeongbu St. Mary’s Hospital were included. The mRNA expression of CD163 and FoxP3 were investigated by quantitative reverse transcription polymerase chain reaction in fresh-frozen breast cancer tissues and adjacent non-cancerous breast tissues. Clinicopathologic parameters including tumor size, lymph node metastasis, stage, the expression status of hormonal (estrogen and/or progesterone) receptor, and human epidermal growth factor receptor-2 were analysed. Also, survival data were reviewed.

Results

Tumor tissues had higher mRNA expression than normal tissues(p 

Conclusions

Our results showed that larger tumor size, advanced stage, lymph node metastasis were associated with high TAMs and TILs infiltration. In addition, high FoxP3 expression was one of the independent prognostic factors for overall survival in breast cancer.

Clinical trial indentification

Legal entity responsible for the study

This study was approved by the Institutuinal review board of Uijeongbu St. Mary\'s hospital(UC16SIS0079)

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.